Amgen Inc's Form 4 filing
Neumora Therapeutics, Inc. (NMRA) · filed Sep 19, 2023
- Accession no.
- 0001610717-23-000289
- Filed
- Sep 19, 2023
- Trade date
- Sep 19, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $30.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Amgen IncCIK 0000318154 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2023 | Common Stock | CConversionAcquired | +33,603,948 | –F1 | – | 33,603,948 | Direct | |
| Sep 19, 2023 | Common Stock | PPurchaseAcquired | +1,764,705 | $17.00 | +$29,999,985 | 35,368,653 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.